Global Bruton Tyrosine Kinase (BTK) Inhibitors Market – Industry Trends and Forecast to 2029

Global Bruton Tyrosine Kinase (BTK) Inhibitors Market, By Type (First Generation, Second Generation), Drug Type (Imbruvica, Calquence, Brukinsa), Application (Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma (SLL), Waldenstrom Macroglobulinemia, Other Selective B Cell Malignancies, Chronic Graft-versus-host Disease, Other), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029.

 Market Analysis and Size

In recent years, the Bruton tyrosine kinase (BTK) inhibitors? market is anticipated to grow rapidly during the forecast period. The B-cell receptor (BCR) signalling pathway includes Bruton's tyrosine kinase (BTK). In different B-cell lymphomas, including chronic lymphocytic leukemia (CLL), Bruton's tyrosine kinase is an essential protein that regulates cell proliferation (growth) and cell survival. As a result, the rationale for employing BTK inhibitors in cancer is to stop this signaling and cause cancer cell death. Hence, rising prevalence of cancer is estimated to increase the demand for Bruton tyrosine kinase (BTK) inhibitors? in healthcare sector.

Data Bridge Market Research analyses that the Bruton tyrosine kinase (BTK) inhibitors? market was valued at USD 9.07 billion in 2021 and is expected to reach USD 16.79 billion by 2029, registering a CAGR of 8.00% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Non-receptor tyrosine kinase inhibitors, such as Bruton tyrosine kinase (BTK) inhibitors, are used to treat B cell diseases, leukaemia, lymphoma, and other cancers. Targeting B-cell receptors affects B-cell signaling, proliferation, and growth. Inhibitors of the Bruton tyrosine kinase (BTK) have shown to be effective in the treatment of haematological malignancies as well as graft versus host disease (GVDH). These inhibitors play a key role in BCR signaling and FcR signaling in myeloid cells.

Report Scope and Market Segmentation

Bruton Tyrosine Kinase (BTK) Inhibitors? Market Dynamics

Drivers

• Increasing prevalence of chronic diseases

The rising prevalence of chronic diseases such as cancer, diabetes and others is anticipated to propel the Bruton tyrosine kinase (BTK) inhibitors? market's growth.  

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of Bruton tyrosine kinase (BTK) inhibitors? market is the rising healthcare expenditure which helps in improving its infrastructure.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the Bruton tyrosine kinase (BTK) inhibitors? market. Additionally, high disposable income and changing lifestyle of people will result in the expansion of Bruton tyrosine kinase (BTK) inhibitors? market. Along with this, rising geriatric population and favourable reimbursement policies will enhance the market's growth rate.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the Bruton tyrosine kinase (BTK) inhibitors? market growth. Along with this, rising drug approvals and launches will further propel the 'market's growth rate.

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the Bruton tyrosine kinase (BTK) inhibitors? market growth during the forecast period.

Restraints/Challenges

On the other hand, the drug approval hindrances and off targeting of first generation Bruton tyrosine kinase (BTK) inhibitors will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the Bruton tyrosine kinase (BTK) inhibitors? market. Additionally, side effects linked with Bruton tyrosine kinase (BTK) inhibitors and increasing prevalence of cardiovascular diseases will act as market restraints and further impede market growth rate during the forecast period of 2022-2029.

This Bruton tyrosine kinase (BTK) inhibitors? market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Bruton tyrosine kinase (BTK) inhibitors? market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Bruton tyrosine kinase (BTK) inhibitors? market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Bruton Tyrosine Kinase (BTK) Inhibitors? Market

Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. This can be ascribed to severe disruptions in their respective manufacturing and supply-chain operations, resulting from multiple precautionary lockdowns and other limitations imposed by governments all over the world. The Bruton tyrosine kinase (BTK) inhibitors market is no exception. Furthermore, consumer preferences has decreased as people are now much more concentrated on removing non-essential expenses from their budgets as the wider economic situation of most people has been adversely impacted by this outbreak. Over the forecast period, the aforementioned factors are likely to have a negative impact on the Bruton tyrosine kinase (BTK) inhibitors market's revenue trajectory.

Global Bruton Tyrosine Kinase (BTK) Inhibitors? Market Scope

The Bruton tyrosine kinase (BTK) inhibitors? market is segmented on the basis of type, drug type, application, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• First Generation
• Second Generation

On the basis of type, the Bruton tyrosine kinase (BTK) inhibitors? market is segmented into first generation, and second generation.

Drug Type

• Imbruvica
• Calquence
• Brukinsa

On the basis of drug type, the Bruton tyrosine kinase (BTK) inhibitors market is segmented into imbruvica, calquence, and brukinsa.

Application

• Chronic Lymphocytic Leukemia (CLL)
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Small Lymphocytic Lymphoma (SLL)
• Waldenstrom Macroglobulinemia
• Other Selective B Cell Malignancies
• Chronic Graft-versus-host Disease
• Others

On the basis of application, the Bruton tyrosine kinase (BTK) inhibitors market is segmented into chronic lymphocytic leukemia (CLL), follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, small lymphocytic lymphoma (SLL), waldenstrom macroglobulinemia, other selective B cell malignancies, chronic Graft-versus-host disease and others.

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

On the basis of end-users, the Bruton tyrosine kinase (BTK) inhibitors? market is segmented into hospitals, specialty clinics, homecare and others.

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

On the basis of distribution channel, the Bruton tyrosine kinase (BTK) inhibitors? market has also been segmented into hospital pharmacy, retail pharmacy, online pharmacy and others.

Bruton Tyrosine Kinase (BTK) Inhibitors? Market Regional Analysis/Insights

The Bruton tyrosine kinase (BTK) inhibitors? market is analysed and market size insights and trends are provided by country, type, drug type, application, end-users and distribution channel as referenced above.

The countries covered in the Bruton tyrosine kinase (BTK) inhibitors? market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the Bruton tyrosine kinase (BTK) inhibitors? market because of the region's growing research and development activities. Additionally, increasing prevalence of chronic diseases and growing presence of major key players will further propel the 'market's growth rate in this region.

Asia-Pacific are expected to grow during the forecast period due to rising healthcare expenditure and improvements in healthcare infrastructure in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Bruton Tyrosine Kinase (BTK) Inhibitors? Market Share Analysis

The Bruton tyrosine kinase (BTK) inhibitors? market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Bruton tyrosine kinase (BTK) inhibitors? market.

Some of the major players operating in the Bruton tyrosine kinase (BTK) inhibitors? market are:

• AbbVie Inc. (US)
• AstraZeneca (UK)
• Johnson & Johnson Private Limited (US)
• Merck & Co., Inc. (US)
• Gilead Sciences, Inc. (US)
• Takeda Pharmaceutical Company Limited (Japan)
• Bristol-Myers Squibb Company (US)
• BeiGene (China)
• InnoCare (China)
• Sanofi (France)
• Novartis AG (Switzerland)
• Carna Biosciences, Inc. (Japan)
• Loxo Oncology (US)
• Aptose Biosciences Inc. (Canada)
• Biogen (US)
• Eli Lilly and Company (US)
• Agilent Technologies, Inc.(US)
• Eternity Bioscience Inc. (US)